Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

ltt pharma limited - budesonide, formoterol fumarate dihydrate - powder for inhalation - 400/12 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics - adrenergics and other drugs for obstructive airway diseases - it is indicated in adults and adolescents aged 12 to17 years for the regular treatment of asthma and for the symptomatic treatment of patients with severe copd

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

astrazeneca ab - budesonide; formoterol fumatrate dihydrate - inhalation powder - 400 mcg/12 microgram(s) - formoterol and budesonide

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - budesonide dihydrate; formoterol fumarate dihydrate - inhalation powder - 400/12 µg/µg - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

merit pharmaceuticals limited - budesonide dihydrate; formoterol fumarate dihydrate - inhalation powder - 400/12 µg/µg - formoterol and budesonide

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 320 microgram; formoterol fumarate dihydrate, quantity: 9 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma rilast turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) rilast turbuhaler is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. rilast turbuhaler is not indicated for the initiation of bronchodilator therapy in copd.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram; formoterol fumarate dihydrate, quantity: 4.5 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma rilast turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) rilast turbuhaler is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. rilast turbuhaler is not indicated for the initiation of bronchodilator therapy in copd.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

imbat limited - budesonide; formoterol fumatrate dihydrate - powder for inhalation - 400mcg/12mcg mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - budesonide; formoterol fumatrate dihydrate - powder for inhalation - 400/12 microgram(s) - o3ak07

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 80 microgram; formoterol fumarate dihydrate, quantity: 4.5 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma rilast turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) rilast turbuhaler is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. rilast turbuhaler is not indicated for the initiation of bronchodilator therapy in copd.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 80ug equivalent to 100 µg metered dose;  ;  ;  ; formoterol fumarate 4.5ug equivalent to 6 µg metered dose;   - powder for inhalation - active: budesonide 80ug equivalent to 100 µg metered dose       formoterol fumarate 4.5ug equivalent to 6 µg metered dose   excipient: lactose monohydrate - symbicort turbuhaler is indicated in the treatment of asthma to achieve overall asthma control, including the prevention and relief of symptoms as well as the reduction of the risk of exacerbations. symbicort turbuhaler is suitable for any asthma severity, where the use of inhaled corticosteroids is appropriate.